Activin and Inhibin

AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 ( AQP4 ) inhibitor for the research of acute ischemic strokeIn VivoAER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and

AES-135, a hydroxamic acid-based pan- HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer . AES-135 inhibits HDAC3 , HDAC6 , HDAC8 , and HDAC11 with IC 50 s ranging from 190-1100 nMIn VitroAES-135 inhibits cancer

AES-135, a hydroxamic acid-based pan- HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer . AES-135 inhibits HDAC3 , HDAC6 , HDAC8 , and HDAC11 with IC 50 s ranging from 190-1100 nMIn VitroAES-135 inhibits cancer

AES-135, a hydroxamic acid-based pan- HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer . AES-135 inhibits HDAC3 , HDAC6 , HDAC8 , and HDAC11 with IC 50 s ranging from 190-1100 nMIn VitroAES-135 inhibits cancer

AES-135, a hydroxamic acid-based pan- HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer . AES-135 inhibits HDAC3 , HDAC6 , HDAC8 , and HDAC11 with IC 50 s ranging from 190-1100 nMIn VitroAES-135 inhibits cancer

AES-135, a hydroxamic acid-based pan- HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer . AES-135 inhibits HDAC3 , HDAC6 , HDAC8 , and HDAC11 with IC 50 s ranging from 190-1100 nMIn VitroAES-135 inhibits cancer

AES-350 is a potent and orally active HDAC6 inhibitor with an IC 50 and a K i of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3 , HDAC8 in an enzymatic activity assay with IC 50 values of 0.187 μM and 0.245 μM, respectively.

AES-350 is a potent and orally active HDAC6 inhibitor with an IC 50 and a K i of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3 , HDAC8 in an enzymatic activity assay with IC 50 values of 0.187 μM and 0.245 μM, respectively.

AES-350 is a potent and orally active HDAC6 inhibitor with an IC 50 and a K i of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3 , HDAC8 in an enzymatic activity assay with IC 50 values of 0.187 μM and 0.245 μM, respectively.

AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC 50 value of 330 nM.In VivoAF38469 (1 mg/kg: i.v.) has a low volume of distribution (blood volume of 0.7 L/kg) and low clearance (4.8 L/h/kg), and a half-life (t1/2) of 1.2 h

AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC 50 value of 330 nM.In VivoAF38469 (1 mg/kg: i.v.) has a low volume of distribution (blood volume of 0.7 L/kg) and low clearance (4.8 L/h/kg), and a half-life (t1/2) of 1.2 h

AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC 50 value of 330 nM.In VivoAF38469 (1 mg/kg: i.v.) has a low volume of distribution (blood volume of 0.7 L/kg) and low clearance (4.8 L/h/kg), and a half-life (t1/2) of 1.2 h